Sam-A Pharm. Co., Ltd (KOSDAQ:009300)
13,560
-130 (-0.95%)
At close: Oct 23, 2026
Sam-A Pharm. Revenue
Sam-A Pharm. had revenue of 18.78B KRW in the quarter ending June 30, 2026, with 7.79% growth. This brings the company's total for the last twelve months to 72.28B, down -12.40% year-over-year. In the year 2025, Sam-A Pharm. had annual revenue of 77.80B, down -18.60%. That makes Sam-A Pharm. the 27,305th largest company in the world by revenue and 1,653rd in South Korea.
Revenue (ttm)
72.28B
Revenue Growth
-12.40%
P/S Ratio
1.14
Revenue / Employee
230.94M
Employees
313
Market Cap
82.76B
Revenue by Geography
- China 77.78B 100.0%
- Overseas 17.00M 0.0%
Fiscal year ended Dec 31, 2025 See the full Sam-A Pharm. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.80B | -17.78B | -18.60% |
| Dec 31, 2024 | 95.58B | -1.63B | -1.68% |
| Dec 31, 2023 | 97.21B | 15.51B | 18.99% |
| Dec 31, 2022 | 81.70B | 27.03B | 49.45% |
| Dec 31, 2021 | 54.67B | 1.01B | 1.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cosmax Nbt | 335.18B |
| H.PIO | 269.63B |
| DongKoo Bio & Pharma | 241.43B |
| Daehan Nupharm | 211.48B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 111.72B |
| KOREA PHARMA | 93.94B |
| Sinil Pharmaceutical | 86.82B |
| High Tech Pharm | 69.41B |